<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197076</url>
  </required_header>
  <id_info>
    <org_study_id>Neoadjuvant study of NSCLC</org_study_id>
    <nct_id>NCT04197076</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA</brief_title>
  <official_title>An Open, Observational Clinical Study, 2 Cycles Treatment as Neoadjuvant Therapy for NSCLC With Stage IIIA (T1-2N2, T3N1, T4N0-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in&#xD;
      stage IIIA NSCLC patients.（Interventional study）&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, observational clinical study, 2 cycles treatment will be planned as&#xD;
      neo-adjuvant therapy for NSCLC participants in stage IIIA (T1-2N2, T3N1, T4N0-1).&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Newly diagnosed Resectable IIIa NSCLC EGFR/ALK/ROS1 TEST PD-L1 TEST Collect puncture biopsy&#xD;
      tissue/ Blood sample in screening period Chest enhanced CT Conditions allowed， whole body&#xD;
      PETCT Exam; Group A：Targeted therapy Tumors with Driver genes （EGFR/ALK/ROS1 Positive） 2&#xD;
      cycles（42 days; Group B：Immunotherapy Enroll Patients from 816 Research treated with&#xD;
      Neoadjuvant immunotherapy Or, treated with immunotherapy in practice（with approval） Group&#xD;
      C：Routine Chemotherapy Driver genes（EGFR/ALK/ROS1 Negative） and PD-L1 Test negative;&#xD;
      Operation （within 6 Ws postoperation） Standard treatment， Allow adjuvant chemotherapy±radioth&#xD;
      erapy Collect resected tissue sample(Tumor T and Node N) /Blood sample; comparisons before&#xD;
      and after treatment: Imaging：CT、PETCT Sample：Tumor tissue、blood&#xD;
&#xD;
      Objective and End point:&#xD;
&#xD;
        1. Main objective and end point：DFS，pCR rate&#xD;
&#xD;
        2. Second objective and end point：OS&#xD;
&#xD;
        3. Exploratory objective and end point：cRR rate、relevant AE、Change of Scoring&#xD;
           Scale、exploration for relevant biological indicators&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DFS: disease free survival</measure>
    <time_frame>36 months</time_frame>
    <description>The time length from randomization(mainly from the receipt of pathology and genetic diagnosis reports)to any of the following events: disease progression, disease recurrence or death from any cause. Disease progression or relapse will be assessed according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pCR: pathologic complete response</measure>
    <time_frame>36 months</time_frame>
    <description>the proportion of patients achieved pathologic complete response（lung and lymph node without tumor residual assessed by pathology review)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS: Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>The time length from the date of randomization (according to the received pathology and genetic diagnosis report) to the date of death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cRR rates</measure>
    <time_frame>approximately 10 weeks After surgery</time_frame>
    <description>The proportion of patients achieved complete or patial remission(Imageological) according to RECIST 1.1 prior to definitive surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Safty AEs</measure>
    <time_frame>36 months</time_frame>
    <description>proportion of delayed or cancelled surgery or duration of surgery or length of hospitalization or surgical procedure, and incidence of AE/SAE associated with surgery, Adverse events will be graded according to NCI CTCAE</description>
  </other_outcome>
  <other_outcome>
    <measure>Qol Quality of Life</measure>
    <time_frame>36 months</time_frame>
    <description>Quality of life asscesed by Quality of Life Questionnare-Core 30(EORTC QLQ-C30）of The European O-rganization for Reasearch and Treatment of Cancer containing 30 items in total. Among them, items 29 and 30 are divided into seven grades. According to the answer options 1 to 7 points. Other items are divided into four grades: none, one point, some to many. When scoring, they are directly rated 1 to 4 points. For functional and overal health domain, higher score means better life quality; for symptom domain ,higher score means worse life quality.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant immunotherapy</arm_group_label>
    <description>pd-1 or pd-l1 inhabitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant targeted therapy</arm_group_label>
    <description>TKIs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <description>chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 or anti-PD-L1</intervention_name>
    <description>immunotherapy anti-PD-1 or anti-PD-L1</description>
    <arm_group_label>Neoadjuvant immunotherapy</arm_group_label>
    <other_name>Neoadjuvant immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR-TKI, ALK inhibitor, ROS1 inhibitor</intervention_name>
    <description>targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor</description>
    <arm_group_label>Neoadjuvant targeted therapy</arm_group_label>
    <other_name>Neoadjuvant targeted therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>investigator decided</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Neoadjuvant chemotherapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Subject's tumor sample obtained within 3 months before enrollment is suitable to be used for&#xD;
      gene testing（EGFR/ALK/ROS1）and PD-L1 testing with Immunohistochemistry (IHC)。&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC participants in stage IIIA (T1-2N2, T3N1, T4N0-1)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary non-small cell lung cancer confirmed by cytology or histology&#xD;
&#xD;
          2. According to the TNM stage (8th Edition) of IASLC lung cancer, it is determined to be&#xD;
             IIIA stage (t1-2n2, t3n1, t4n0-1) non-small cell lung cancer, which is considered to&#xD;
             be resectable;&#xD;
&#xD;
          3. There must be at least one evaluable focus judged according to rrecist1.1 standard&#xD;
             (the longest diameter on spiral CT is at least 10 mm, and the longest diameter on&#xD;
             general CT is at least 20 mm)&#xD;
&#xD;
          4. ECoG PS 0 or 1&#xD;
&#xD;
          5. There are tumor samples available for gene detection (EGFR / ALK / ros1) and PD-L1&#xD;
             immunohistochemistry (IHC) in the subjects, and the tumor samples should be obtained&#xD;
             within 3 months before enrollment.&#xD;
&#xD;
          6. If all suspected mediastinal lymph nodes (including those with pathological&#xD;
             enlargement or FDG concentration on PET / CT) can be examined by EBUS, thoracoscopy or&#xD;
             mediastinoscopy, further sampling is required for pathological confirmation.&#xD;
&#xD;
          7. Male or female, ≥ 18 years old&#xD;
&#xD;
          8. Adequate blood function: absolute neutrophil count (ANC) ≥ 2 × 109 / L, platelet count&#xD;
             ≥ 100 × 109 / L and hemoglobin 110 ≥ 9 g / dl&#xD;
&#xD;
          9. Adequate liver function: total bilirubin ≤ upper limit of normal value (ULN); AST and&#xD;
             alt ≤ upper limit of normal value (ULN); alkaline phosphatase ≤ upper limit of normal&#xD;
             value (ULN)&#xD;
&#xD;
         10. Adequate renal function: serum creatinine ≤ upper limit of normal value (ULN) or&#xD;
             calculated creatinine clearance ≥ 60ml / min&#xD;
&#xD;
         11. No anti-tumor drug treatment in the past&#xD;
&#xD;
         12. For patients who have had previous surgery, it is required that more than 4 weeks have&#xD;
             passed since the start of study treatment, and the patients have recovered&#xD;
&#xD;
         13. Women with a full uterus must have negative pregnancy test results within 28 days&#xD;
             before entering the study (unless it is 24 months after amenorrhea). If the pregnancy&#xD;
             test is more than 7 days from the first administration, a urine pregnancy test is&#xD;
             required for verification (within 7 days before the first administration)&#xD;
&#xD;
         14. Sign the informed consent form (the informed consent form needs to be approved by the&#xD;
             independent ethics committee, and the informed consent of the patient should be&#xD;
             obtained before starting any substantive trial procedure)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have other malignant tumors in the last 5 years&#xD;
&#xD;
          2. AST and / or ALT &gt; 2.5 times of the upper limit of normal value (ULN), with alkaline&#xD;
             phosphatase &gt; 5 times of the upper limit of normal value (ULN)&#xD;
&#xD;
          3. Previously received radiotherapy&#xD;
&#xD;
          4. Previously used chemotherapy drugs, targeted and immunotherapy drugs (except&#xD;
             bisphosphonates)&#xD;
&#xD;
          5. There are any uncontrolled systemic diseases, including active infection, uncontrolled&#xD;
             hypertension, diabetes, unstable angina, congestive heart failure, myocardial&#xD;
             infarction (within 1 year before treatment), serious arrhythmia requiring drug&#xD;
             treatment, liver, kidney and metabolic diseases&#xD;
&#xD;
          6. Women in pregnancy or lactation&#xD;
&#xD;
          7. The patient (male or female) has the possibility of childbearing but is unwilling or&#xD;
             does not take effective contraceptive measures&#xD;
&#xD;
          8. Receive the experimental treatment of other clinical studies at the same time (in the&#xD;
             treatment period of clinical studies)&#xD;
&#xD;
          9. Known to be allergic to possible chemotherapy drugs&#xD;
&#xD;
         10. There is evidence of other diseases, neurological or metabolic dysfunction, abnormal&#xD;
             physical examination or laboratory examination, and it is suspected that there may be&#xD;
             a high risk of contraindications to the study drug or complications related to&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Lu</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shun D Lu</last_name>
    <phone>86-21-62821990</phone>
    <phone_ext>15216769608</phone_ext>
    <email>shunlu@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaxian Yao</last_name>
    <phone>15216769608</phone>
    <email>yaxianyao@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department, Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaxian Yao</last_name>
      <phone>15216769608</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Lu Shun</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

